HomeInsightsStock Comparison

Alembic Pharmaceuticals Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Alembic Pharmaceuticals Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: Jun 07, 2025

Key Highlights

  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 987.85 as of 06 Jun 15:30.
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 12.1 on March 2020 to 31.4 on March 2024 . This represents a CAGR of 21.01% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 40.6 on March 2024 . This represents a CAGR of 12.53% over 5 years.
  • The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 10059 crore on March 2020 to ₹ 19309 crore on March 2024 . This represents a CAGR of 13.93% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 388812 crore on March 2024 . This represents a CAGR of 35.70% over 5 years.
  • The revenue of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 1783 crore as compare to the Dec '24 revenue of ₹ 1702 crore. This represent the growth of 4.77% The revenue of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 13571 crore as compare to the Dec '24 revenue of ₹ 14141 crore. This represent the decline of -4.03%.
  • The ebitda of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 285.46 crore as compare to the Dec '24 ebitda of ₹ 270.08 crore. This represent the growth of 5.69% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 3967 crore as compare to the Dec '24 ebitda of ₹ 4158 crore. This represent the decline of -4.6%.
  • The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 120.6 crore to ₹ 156.63 crore over 8 quarters. This represents a CAGR of 13.96% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 2160 crore over 8 quarters. This represents a CAGR of 3.60% .
  • The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 19.45 % on March 2020 to 32.44 % on March 2024 . This represents a CAGR of 10.77% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 113.33 % on March 2024 . This represents a CAGR of 30.55% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business.
  • As per the scheme of arrangement, the 'Pharmaceutical Undertaking' of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Sun Pharmaceuticals Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharma slips as USFDA issues four observations for Panelav API facility

According to a regulatory filing, the USFDA conducted an unannounced and routine current g...

Read more

02 Jun 2025 11:58

News

Alembic Pharma receives USFDA final approval for Bosutinib tablets

Bosutinib tablets are indicated for the treatment of adult patients with chronic, accelera...

Read more

30 May 2025 15:42

News

Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets

Amlodipine and Atorvastatin tablets are a combination medication used to treat high blood ...

Read more

23 May 2025 15:08

News

Alembic Pharmaceuticals receives USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from...

Read more

15 May 2025 14:14

News

Alembic Pharma rises on USFDA approval for Rivaroxaban Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

15 May 2025 16:36

News

Board of Alembic Pharmaceuticals recommends final dividend

Alembic Pharmaceuticals announced that the Board of Directors of the Company at its meetin...

Read more

06 May 2025 14:39

Sun Pharmaceutical Industries Ltd News Hub

News

Board of Sun Pharmaceutical Industries appoints director

The Board of Sun Pharmaceutical Industries at its meeting held on 22 May 2025 has approved...

Read more

23 May 2025 11:13

News

Sun Pharmaceutical Industries announces cessation of director

The Board of Sun Pharmaceutical Industries at its meeting held on 22 May 2025 has noted th...

Read more

23 May 2025 11:14

News

Sun Pharma drops after Q4 PAT slides 19% YoY to Rs 2,1450 cr

Profit before tax (PBT) jumped 15.6% YoY to Rs 3,254.35 crore in Q4 FY25. During the quart...

Read more

23 May 2025 13:48

News

Sun Pharmaceuticals Industries AGM scheduled

Sun Pharmaceuticals Industries announced that the 33th Annual General Meeting(AGM) of the ...

Read more

23 May 2025 15:37

News

Board of Sun Pharmaceuticals Industries recommends final dividend

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its...

Read more

22 May 2025 20:47

News

Sun Pharmaceutical Industries Ltd Spurts 2.83%, BSE Healthcare index Rises 1.26%

Sun Pharmaceutical Industries Ltd rose 2.83% today to trade at Rs 1733.95. The BSE Healthc...

Read more

13 May 2025 09:30

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Sun Pharmaceuticals Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 19,417 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 403,076 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

As of June 7, 2025, the Alembic Pharmaceuticals Ltd stock price is INR ₹987.85. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1679.95.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions